ProMIS Neurosciences (PMN) vs Retension Pharmaceuticals (RTSN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 12, 2026.
Summary
Retension Pharmaceuticals is the larger company by market cap ($89.2 million vs $84.7 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Head-to-head
| Metric | PMN | RTSN |
|---|---|---|
| Share price | $9.45 | $11.32 |
| Market cap | $84.74M | $89.22M |
| 1-day change | -1.66% | +7.50% |
| YTD return | +38.36% | — |
| 1-year return | -21.25% | — |
| 5-year return | -95.80% | — |
| EPS (TTM) | $-11.65 | $-2.61 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $27.40 | $11.79 |
| 52-week low | $6.27 | $9.66 |
| Distance from 52-week high | -65.51% | -3.99% |
| Analyst consensus | none | — |
| Avg. price target upside | +350.90% | — |
| Average volume | 82.46K | 789.20K |
| Shares outstanding | 8.97M | 7.88M |
| Employees | 10 | 12 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About ProMIS Neurosciences
PMN stock →ProMIS Neurosciences, Inc. discovers and develops antibody therapies and therapeutic vaccines for neurodegenerative diseases and other misfolded protein diseases in Canada.
Health Care · Biotechnology: Pharmaceutical Preparations · 10 employees
About Retension Pharmaceuticals
RTSN stock →Retension Pharmaceuticals, Inc. operates as a clinical -stage biopharmaceutical company focused on developing medicines for the treatment of hypertension and other cardiovascular diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 12 employees
PMN vs RTSN FAQ
Which is bigger, ProMIS Neurosciences or Retension Pharmaceuticals?
Retension Pharmaceuticals (RTSN) is larger, with a market capitalization of $89.22M compared with $84.74M for ProMIS Neurosciences (PMN).
Are ProMIS Neurosciences and Retension Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.